SCIENTIFIC LITERATURE · MED

CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.

Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M.

Drug Metab Dispos · 2001-11-01

PMID: 11602525

Check source for accessResearch Support, Non-U.S. Gov't; Journal ArticleOriginal source ↗

Research overview

This section identifies the original publication. Follow the source for its authors and journal.

Assess the question within the original study’s scope.

Check the source article for study design and sample details.

An editorially approved findings summary is not yet published for this record.

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.